# Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

> **NCT05695417** · PHASE1 · UNKNOWN · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 21 (estimated)

## Conditions studied

- Non-proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** OTX-TKI
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT05695417
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-15
- **Primary completion:** 2024-01
- **Final completion:** 2024-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05695417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05695417, "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05695417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*